Format

Send to

Choose Destination
Monoclon Antib Immunodiagn Immunother. 2018 Apr;37(2):110-115. doi: 10.1089/mab.2018.0004. Epub 2018 Apr 2.

Monoclonal Antibody L1Mab-13 Detected Human PD-L1 in Lung Cancers.

Author information

1
1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Japan .
2
2 Department of Pathology and Laboratory Medicine, Sendai Medical Center , Sendai, Japan .
3
3 New Industry Creation Hatchery Center, Tohoku University , Sendai, Japan .

Abstract

Programmed cell death ligand-1 (PD-L1) is a type I transmembrane glycoprotein expressed on antigen-presenting cells. It is also expressed in several tumor cells such as melanoma and lung cancer cells. A strong correlation has been reported between human PD-L1 (hPD-L1) expression in tumor cells and negative prognosis in cancer patients. Here, a novel anti-hPD-L1 monoclonal antibody (mAb) L1Mab-13 (IgG1, kappa) was produced using a cell-based immunization and screening (CBIS) method. We investigated hPD-L1 expression in lung cancer using flow cytometry, Western blot, and immunohistochemical analyses. L1Mab-13 specifically reacted hPD-L1 of hPD-L1-overexpressed Chinese hamster ovary (CHO)-K1 cells and endogenous hPD-L1 of KMST-6 (human fibroblast) in flow cytometry and Western blot. Furthermore, L1Mab-13 reacted with lung cancer cell lines (EBC-1, Lu65, and Lu99) in flow cytometry and stained lung cancer tissues in a membrane-staining pattern in immunohistochemical analysis. These results indicate that a novel anti-hPD-L1 mAb, L1Mab-13, is very useful for detecting hPD-L1 of lung cancers in flow cytometry, Western blot, and immunohistochemical analyses.

KEYWORDS:

lung cancer; monoclonal antibody; programmed cell death-ligand 1

PMID:
29608408
DOI:
10.1089/mab.2018.0004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center